Navigation Links
InterMune Reports First Quarter 2013 Financial Results and Business Highlights
Date:4/24/2013

in a range of $100 to $120 million.
  • SG&A expense: currently anticipated to be in a range of $145 to $165 million.
  • Total Operating Expenses (R&D and SG&A): currently anticipated to be in a range of $245 to $285 million.  
  • Conference Call and Webcast DetailsInterMune will host a live webcast of a conference call today at 4:30 p.m. EDT to discuss business highlights and financial results for the first quarter 2013.  Interested investors and others may participate in the conference call by dialing 800-891-8257 (U.S.) or +1-212-271-4651 (international), conference ID# 21655193.  A replay of the webcast and teleconference will be available approximately three hours after the call.

    To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

    A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 800-633-8284 (U.S.) or +1 402-977-9140 (international), and entering the conference ID# 21655193.  The webcast will remain available on the company's website until the next earnings call.

    About InterMune
    InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.  In pulmonology, the company is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive, irreversible, unpredictable and ultimately fatal lung disease.  Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU and Canada as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States.  InterMune's research programs are focus
    '/>"/>

    SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
    2. InterMune to Present at J. P. Morgan Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune To Present At JMP Securities Healthcare Conference
    5. InterMune To Release Third Quarter Financial Results On November 7
    6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
    7. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
    8. InterMune To Release First Quarter Financial Results On April 24
    9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. ... (eslicarbazepine acetate) for use as a once-daily adjunctive ... with epilepsy who are not satisfactorily controlled with conventional ... in patients under 18 years of age. ... disorders and according to Epilepsy Canada, it affects 0.6% ...
    (Date:7/11/2014)... AZ (PRWEB) July 11, 2014 ... device company specializing in the soft tissue reconstruction ... All-Suture Anchor System for surgeries involving the shoulder ... fixation through a novel, inserter-controlled deployment method. The ... to partial deployment, anchor pull-out, or anchor displacement ...
    (Date:7/10/2014)... 10, 2014 Product and process ... low abundance and are often “lost in the ... , Join presenters Dr. Rowel Tobias, Senior Scientist, ... Anders, Head of Quality at Nanotherapeutics, Inc., to ... can speed detection and quantitation while achieving the ...
    (Date:7/10/2014)... Understanding the need for better quality ... the gap that currently exists in this area, ChanTest ... portfolio of validated ion channel and GPCR cell lines. ... as ion channels control many critical physiological functions throughout ... the potential to treat a variety of human diseases. ...
    Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3
    ... product ideas to market, RESEARCH TRIANGLE PARK, N.C., ... to $1 million in loans under,a program unveiled this ... loans are part of an expanded program funded by ... give early-stage,companies a boost before they become competitive for ...
    ... Nargis, a category 3 tropical storm that struck the low-lying and ... Agriculture Service (FAS) of the U.S. Department of Agriculture (USDA) began ... damaged agricultural areas to accompany its commodity intelligence reports. , ... ...
    ... July 9 Brinks Hofer Gilson & Lione, one of ... opening,of a new office in the Raleigh/Durham, North Carolina area ... T. Elliott, who will be,based in the Raleigh office. Mr. ... the firm as partners. The office will officially,be open for ...
    Cached Biology Technology:N.C. Biotech Center Launches Larger Loans 2Myanmar's Cyclone-Damaged Rice Production Regions Monitored with GIS 2Myanmar's Cyclone-Damaged Rice Production Regions Monitored with GIS 3Brinks Hofer Gilson & Lione Expands to High-Tech Raleigh/Durham Area; Adds Accomplished Patent Attorneys to Its New Office 2Brinks Hofer Gilson & Lione Expands to High-Tech Raleigh/Durham Area; Adds Accomplished Patent Attorneys to Its New Office 3
    (Date:7/11/2014)... including scientists from the Max Planck Institute for Medical ... step in understanding photosynthesis, the process by which the ... its atmosphere and which is therefore crucial for all ... researchers report the first direct visualization of a crucial ... which a specific protein complex, photosystem II, splits water ...
    (Date:7/11/2014)... risk of kidney injury related to the use of ... of HES molecules, according to a report in ... Anesthesia Research Society (IARS). , The "total mass of ... cultured human renal proximal tubule cells (PTCs), concludes the ... University Hospital Wrzburg, Austria. Other factorssuch as differences ...
    (Date:7/11/2014)... is evidence that under the normal circumstances, ... development, maintain neuronal environment, and exhibit therapeutic ... neurodegenerative disease. Previous studies have found that ... after chemical induction have reduced viability, which ... Prof. Xiaodong Yuan, Kailuan General Hospital, Hebei ...
    Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
    ... paper published in the January issue of the journal ... including William A. Masters, a professor at the Friedman School ... new approach to monitoring the relationship between nutrition and child ... of surveys compiled over 20 years, changes in the number ...
    ... January 31, 2011 A scientist from The Scripps Research Institute ... in preventing blood clot formation. The molecule could become a ... blood clotting diseases such as Hemophilia A. The findings, ... Mosnier, were published in a recent edition of Journal ...
    ... In order for medical students to ultimately provide quality patient ... teach physiology, one of the core disciplines of medicine, according ... Journal of the American College of Radiology ( www.jacr.org ... systems. "It is vital that medical schools provide ...
    Cached Biology News:New approach suggested for monitoring child health in developing countries 2Scripps Research scientist discovers natural molecule indirectly prevents stable clot formation 2Scripps Research scientist discovers natural molecule indirectly prevents stable clot formation 3
    ... deuterium atoms at the 9, 10, 12, and ... an internal standard for the quantification of 13(S)-HODE ... by incubation of linoleic acid with plant and ... the adhesion of tumor cells to the endothelium ...
    ...
    ...
    DryStrip aligners, 4. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
    Biology Products: